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In this issue of Cancer Cell, Gruber et al. report that a significant proportion of children with acute megakar-
yoblastic leukemia acquire a translocation that confers enhanced BMP signaling and promotes self-renewal
of hematopoietic progenitors. This study presents novel therapeutic targets that may lead to improved ther-
apies for this aggressive leukemia.Acutemegakaryoblastic leukemia (AMKL)
is a rare and deadly form of acute myeloid
leukemia. There are three major subtypes
of AMKL that differ from one another in
their genetics and their prognosis:
leukemia found in children with Down
syndrome (DS), in children without DS,
or in adults. Of these groups, the patho-
genesis of DS-AMKL has the greatest
clarity. Nearly 5% of children with
DS-AMKL acquire GATA1 mutations in
mid-gestation that lead to abnormal
megakaryocyte development. It is be-
lieved that the combination of a GATA1
mutation and aberrant expression of
ERG and DYRK1A, among other genes
on chromosome 21, promotes a pre-
leukemia named transient myeloprolifera-
tive disorder (TMD) (Malinge et al., 2012).
Evolution of TMD to AMKL likely requires
the acquisition of additional mutations in
genes such as MPL and JAK2, which are
associated with aberrant megakaryopoie-
sis in the myeloproliferative neoplasms
(MPNs). It is also believed that GATA1
mutations confer hypersensitivity to treat-
ment with cytosine arabinoside, which
leads to a favorable outcome (Ge et al.,
2004). In sharp contrast, adults with
AMKL face a dismal prognosis, with
nearly all patients relapsing within one
year of diagnosis (Tallman et al., 2000).
Apart from sporadic mutations in JAK2
andMPL, little is known about the genetic
basis of adult AMKL.
Although there have been many revela-
tions about pediatric AMKL in children
with DS, much less is known about the
etiology of other pediatric cases. Oneexception is the presence of a recurring
(1;22) translocation, which creates the
OTT-MAL (or RBM15-MKL1) fusion
unique to pediatric AMKL. This fusion
leads to altered expression of serum
response factor target genes and aber-
rant Notch pathway activation (Cheng
et al., 2009; Mercher et al., 2009). Addi-
tionally, rare findings of JAK and MPL
mutations have also been observed in
this group.
To identify new mutations and chromo-
somal aberrations that define pediatric
AMKL, Gruber et al. (2012; this issue
of Cancer Cell) took advantage of next-
generation sequencing, a powerful tool
that provides new insights into the
genetics of cancer. Paired-end se-
quencing of a discovery cohort consisting
of 14 pediatric non-DS AMKL patients
revealed structural variations that led to
novel chimeric transcripts in 12 of the
cases. Of note, half of the AMKL cases
harbored a cryptic inversion on chromo-
some 16 inv(16)(p13.3q24.3), which led
to fusion of CBFA2T3 and GLIS2. Two of
these cases with the CBFA2T3-GLIS2
fusion also had a gain of chromosomal
arm 21q, a common abnormality in
AMKL. Remarkably, after screening a
larger validation cohort and other
leukemia samples, the fusion was de-
tected in 27% of pediatric non-DS AMKL
cases. The CBFA2T3-GLIS2 fusion was
not observed in adult AMKL nor in any
other form of myeloid leukemia. In addi-
tion, none of the samples with inv(16)
(p13.3q24.3) had t(1;22), suggesting that
these two recurring translocations areCancer Cell 22, Nmutually exclusive. Surprisingly, seven
cases, including three cases with the
novel fusion, also contained amplification
of the Down syndrome critical region,
implying that dysregulation of Hsa21
genes contributes to more than just the
DS subtype of AMKL (Gruber et al., 2012).
CBFA2T3 is a member of the ETO
family of co-repressors that is expressed
in hematopoietic cells and plays a role in
regulating stem cell quiescence (Chyla
et al., 2008). In contrast, the gene encod-
ing GLIS2, which participates in the regu-
lation of SHH signaling, is not expressed
in hematopoietic cells. However, as a
consequence of the fusion, the C-terminal
zinc finger domain that binds the GLIS
consensus sequence is fused to the
N-terminal CBFA2T3 nervy domain that
mediates protein-protein interactions
and is expressed in blood cells. Gene
expression studies comparing fusion-
positive AMKLs against other forms of
AML revealed that cases with the fusion
showed altered expression of genes in
the BMP, SHH, and WNT pathways. In
particular, marked overexpression of
BMP2andBMP4was observed (Figure 1).
Of note, expression of CBFA2T3-GLIS2
or GLIS2 alone in Drosophila led to
enhanced BMP signaling and the associ-
ated dpp gain-of-function phenotype,
including shortened legs and wing blis-
tering (Gruber et al., 2012).
The discovery of this novel recurring
translocation raises a number of im-
portant questions. First, is the fusion
a necessary and/or sufficient factor
in leukemogenesis? Functional studiesovember 13, 2012 ª2012 Elsevier Inc. 567
Figure 1. Model of the Activity of inv(16)(p13.3q24.3) Gene Fusion
Product in AMKL
The CBFA2T3-GLIS2 fusion protein generated by inv(16)(p13.3q24.3) likely
directly activates transcription of activators of BMP signaling BMP2 and
BMP4 as well as inhibitors of SHH signaling PTCH and HHIP. BMP2/4 may
act in an autocrinemanner to foster growth of AMKL blasts or may alternatively
signal in a paracrine manner to hematopoietic progenitors that, in turn, would
promote the megakaryocytic lineage phenotype of the leukemia. In addition,
mutations in MPL or JAK family members confer cytokine independence
and likely cooperate with the fusion to promote AMKL.
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sion of the fusion protein, or
GLIS2 alone, led to enhanced
self-renewal of hematopoi-
etic progenitors in vitro. This
phenotype was blocked by
dorsomorphin, a small mole-
cule that interferes with BMP
signaling to Smad effectors,
suggesting that the increased
expression of BMP down-
stream of the fusion is
essential for the phenotype.
Expression of the CBFA2T3-
GLIS2 fusion transcript in
mice, however, did not lead
to leukemia, indicating that
the fusion protein is not suffi-
cient for leukemogenesis. It is
likely that mutations, which
confer cytokine independent
growth, such as those in
MPL or JAK family members,
cooperate with the fusion to
promote AMKL.
Second, is thereacontribu-
tion by CBFA2T3 apart from
driving expression of GLIS2
in hematopoietic cells? The
finding that GLIS2 trans-duced hematopoietic progenitors failed
to re-plate to the same extent as progen-
itors transduced with the fusion strongly
suggests that there is an additional, as
yet undefined, contribution by CBFA2T3.
Alternatively, it is possible that loss of
the N-terminal amino acids of GLIS2 in
the fusion may alter GLIS2 function.
Third, what is the natural history of the
disease? GATA1 mutations in DS-AMKL
originate in the fetal liver and can be de-
tected as early as 21 weeks of gestation
(Taub et al., 2004). However, although
GATA1 mutations in DS are suspected to
cause TMD, not all babies with GATA1
mutations show an overt hematopoietic
phenotype, and the majority do not go on
to develop AMKL. This finding is reminis-
cent of classical studies by Greaves and
Wiemels (2003), who showed that chro-
mosomal translocations can be detected
at birth even in children who do not go on
to develop leukemia. The timing of the
pediatric non-DS AMKL suggests that
the fusion of CBFA2T3 and GLIS2 occurs
in utero and within the fetal liver. Whether
all instances of the fusion lead to leukemia568 Cancer Cell 22, November 13, 2012 ª20remains to bedetermined, but the fact that
expression of CBFA2T3-GLIS2 in mice
does not confer leukemia suggests that
additional events are required for full
transformation. Similar to GATA1 muta-
tions, the fusion is not detected in adult
AMKL, implying perhaps that necessary
cooperating events are not possible in
bone marrow progenitors.
Fourth, how does the translocation
specifically lead to pediatric AMKL?
Previous studies have shown that in-
creased BMP signaling induces the differ-
entiation of CD34+ cells to megakaryo-
cytes (Jeanpierre et al., 2008). This effect
may be the result of upregulation of JAK/
STAT signaling, as seen in MPNs and
AMKL with activating mutations in MPL
and JAK family members. However, the
details of how activated BMP signaling,
downstream of the CBFA2T3-GLIS2
fusion protein, imparts a megakaryocytic
phenotype remains a mystery.
Finally, will BMP inhibitors prove to be
effective new therapies for AMKL? Given
the poor prognosis of AMKL and, in partic-
ular, cases with the CBFA2T3-GLIS212 Elsevier Inc.fusion, development of novel
therapies is essential. The
observation that a BMP
antagonist disrupts re-plating
of hematopoietic progenitors
suggests that inhibition of
BMP signaling may provide
therapeutic benefit. However,
additional events that coop-
erate with the fusion to drive
acute leukemia may circum-
vent anti-BMP therapy. Future
preclinical and, if appropriate,
clinical studies to determine
the effectiveness of BMP
inhibitors against human
AMKL are needed.REFERENCES
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